Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celgene Corporation CELG

Healthcare Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma... see more

Recent & Breaking News (NDAQ:CELG)

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY

PR Newswire November 18, 2021

BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY

PR Newswire November 17, 2021

Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company

Newsfile October 28, 2021

CELG Investor Alert: Class Action Lawsuit Filed Against Bristol-Myers Squibb Company

Newsfile October 23, 2021

NASDAQ: CELG Investor Notice: Update in Lawsuit against Celgene Corporation announced by Shareholders Foundation

ACCESSWIRE IA January 7, 2020

NexImmune Appoints Sol Barer as Chairman of the Board of Directors

GlobeNewswire December 16, 2019

Amgen Completes Acquisition Of Otezla® (apremilast)

PR Newswire November 21, 2019

Celgene Announces Plans to Transfer Listing of Celgene's Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb

Business Wire November 20, 2019

Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

PR Newswire November 19, 2019

Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019

GlobeNewswire November 18, 2019

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Canada NewsWire November 12, 2019

FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire November 8, 2019

Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting

Business Wire November 6, 2019

Celgene Reports Third Quarter 2019 Operating and Financial Results

Business Wire October 31, 2019

Celgene and the Multiple Sclerosis Association of America Take the MS MindShift Initiative and "Brain Bulb" Hot Air Balloon to the Sky at Owl-O-Ween Festival to Educate on Multiple Sclerosis and Brain Health

Business Wire October 16, 2019

Celgene Corporation Names Second Round of Celgene Cancer Care Links(TM) Program Grant Recipients

Business Wire September 20, 2019

Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints

Business Wire September 12, 2019

Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Business Wire September 9, 2019

Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

PR Newswire August 26, 2019

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis

Business Wire August 16, 2019